Calcium Verla

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcium Verla

What is Calcium Verla? Defining the Supplement

Property Description
Active ingredients Calcium carbonate, Colecalciferol (Vitamin D3)
Form Effervescent tablet
Pharmacological Class Mineral/Electrolyte Supplement and Vitamin D analog
Common Use Maintaining bone health and addressing deficiencies
Origin Combination of essential mineral and vitamin

Calcium Verla is a combination supplement that provides the essential mineral calcium and Colecalciferol (Vitamin D3) in a single product. It is classified broadly as a Mineral/Electrolyte Supplement and a Vitamin D analog. This formulation is manufactured by Verla-Pharm Arzneimittel GmbH & Co. KG in Germany.

The active ingredients are calcium carbonate, a concentrated source of elemental calcium, and Colecalciferol (Vitamin D3). This combination is clinically recognized for its role in preventing and managing nutritional deficiencies. The product is often distinguished by its effervescent form, designed to be dissolved in water, which makes the supplement easier to consume for individuals who struggle with swallowing tablets.


Why Calcium and Vitamin D are Paired in One Product

The combination of calcium and Vitamin D3 in Calcium Verla is necessary because the body requires Vitamin D3 to efficiently absorb and use calcium. Calcium is the body's most abundant mineral, crucial for forming and maintaining strong bones and teeth. It plays a fundamental role in supporting not only skeletal structure but also muscle function and nerve signaling.

By combining them, the supplement ensures that the patient receives both the vital material and the necessary cofactor needed to successfully support mineral homeostasis. This combined approach is frequently used when a patient needs to address a potential deficiency in both components, such as when supporting bone health in older adults or during periods of inadequate sun exposure.


How Calcium Verla is Supplied (Effervescent Form)

Calcium Verla is supplied as an effervescent tablet, a form that must be fully dissolved in water before being taken orally. The effervescent nature, a distinctive feature of this specific product line, allows the active ingredients to already be in a dissolved state upon consumption.

This specific format is often preferred as it may improve gastrointestinal tolerance and is especially beneficial for patients with difficulty swallowing. The route of administration is strictly oral as a prepared solution.

What side effects are possible with Calcium Verla?

Possible Side Effects and Safety Information

The safety profile for this combination of calcium carbonate and colecalciferol is established through regulatory classifications based on frequency and affected body system. Adverse reactions are formally grouped into categories reflecting their incidence in clinical use, focusing primarily on metabolic balance and gastrointestinal function.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency according to official regulatory standards:

  • Uncommon (affecting 1 to 10 users in 1,000):

    • Hypercalcaemia (elevated calcium in the blood)
    • Hypercalciuria (elevated calcium in the urine)
  • Rare (affecting 1 to 10 users in 10,000):

    • Gastrointestinal disturbances, including constipation, flatulence, nausea, abdominal pain, and diarrhoea.
    • Hypersensitivity reactions, such as pruritus (itching) and rash.

Serious Adverse Reactions and Safety Constraints

The most significant safety considerations often relate to high cumulative exposure or specific patient vulnerabilities. Documented serious adverse reactions associated with chronic high-dose use include Milk-Alkali Syndrome and the formation of Nephrolithiasis (kidney stones). Risk is also managed by monitoring.

Population-Specific Safety Considerations are defined in official documents for certain groups. Patients with renal impairment require careful monitoring due to an increased risk of hypercalcaemia and calcification. Similar caution is documented for patients with sarcoidosis and immobilised patients with osteoporosis.

For long-term treatment, regulatory documents state that monitoring of blood calcium, urine calcium, and kidney function is required to manage potential exposure-related risks. Safety restrictions also highlight the need for close observation when used concurrently with certain medications, such as thiazide diuretics or cardiac glycosides.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Calcium Verla, a combination of calcium carbonate and Colecalciferol (Vitamin D3), results in toxic effects primarily related to hypercalcaemia and excessive Vitamin D levels, as documented in official regulatory labeling. These effects can range from mild to life-threatening.


Documented Overdose Manifestations

System Official Regulatory Statement
Gastrointestinal Nausea, vomiting, loss of appetite (anorexia), constipation, abdominal pain.
Systemic/Renal Fatigue, muscle weakness, headache, excessive thirst (polydipsia), and excessive urination (polyuria).
Severe Outcomes Risk of irreversible renal damage, cardiac arrhythmias (shortened QT interval), and altered consciousness leading to coma or encephalopathy.

Required Emergency Actions

Regulatory authorities mandate that all intake of the product and any other calcium or Vitamin D supplements must be immediately stopped upon suspicion of overdose. Patients must seek immediate medical attention or contact emergency services right away if symptoms are severe or persistent. Officially described management procedures involve aggressive rehydration and may include specific pharmacological interventions like bisphosphonates in a hospital setting. Hospital monitoring is required to assess serum calcium levels, kidney function, and ECG.

Therapeutic Uses of Calcium Verla

What Calcium Verla Treats: Main Uses and Benefits

Calcium Verla is commonly used when short-term symptomatic assistance is needed, and is applied across domains where additional symptomatic support is needed. Regarding its active ingredients, the supplement may be applied to relieve symptoms that create noticeable physiological strain, such as symptoms related to physical discomfort. This application provides supportive relief that helps ease the overall symptom burden.

The medication is commonly used for managing symptoms related to systemic imbalance, and is relevant in contexts involving heightened systemic burden. It is relevant in situations involving recurrent or episodic manifestations.

“It supports general well-being during symptomatic phases.”

This medicine is relevant in contexts marked by increased discomfort or tension, especially across conditions involving episodic or fluctuating manifestations. It helps maintain a sense of stability when symptoms are more noticeable, and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory eligibility for Calcium Verla (Calcium Carbonate and Colecalciferol/Vitamin D3) is defined by conditions that may be worsened by, or contraindicate, the use of supplemental calcium and Vitamin D. The product is generally allowed for use in adults for deficiency management.


Contraindicated Populations

Use of this medicine is absolutely contraindicated for patients with pre-existing imbalances in mineral levels, including hypercalcaemia (high calcium in the blood) and hypervitaminosis D (high Vitamin D levels) [Source 1.1]. It must not be used by individuals with hypercalciuria (excess calcium in the urine), existing kidney stones (nephrolithiasis), or severe renal impairment [Source 1.1]. Hypersensitivity to the active ingredients or any excipients is also an absolute contraindication [Source 1.1].


Age-Related and Conditional Restrictions

  • Pediatric Use: The product is not intended for use in children and adolescents (typically under 18 years) [Source 1.1]. The high concentration of Vitamin D in the medicinal product determines this restriction.
  • Renal Impairment: For patients with non-severe renal impairment, use requires caution and monitoring of calcium and phosphate levels to prevent hypercalcaemia and soft tissue calcification [Source 1.1].
  • Pregnancy and Lactation: Use during pregnancy is generally permitted but requires adherence to officially defined daily intake limits for calcium and Vitamin D [Source 1.5]. During lactation, official labeling states it is not recommended in some cases, as the active substances pass into maternal milk [Source 1.1].

What should I know about interactions with other medicines?

The interaction profile for Calcium Verla is defined by two primary regulatory concerns: altering the absorption of other medicines and generating additive effects on mineral levels.

Co-administration of the calcium component with certain oral medications is documented to significantly reduce the absorption and systemic exposure of the co-administered drug. This includes the thyroid hormone Levothyroxine, bone agents like Bisphosphonates (such as Alendronate), and various Tetracycline or Fluoroquinolone antibiotics. Regulatory documentation advises mandatory timing separation for these combinations; for example, Bisphosphonates must be separated by at least 30 minutes, and Levothyroxine by at least four hours to minimize the absorption interference.

A significant pharmacodynamic interaction is the increased risk of toxicity when co-administered with Cardiac Glycosides (like Digoxin), which is documented to exacerbate arrhythmias. Combining this supplement with Thiazide Diuretics (such as Hydrochlorothiazide) is also documented to increase the risk of hypercalcemia due to reduced urinary calcium excretion.

Other documented exposure-altering patterns involve Colecalciferol (Vitamin D3). Its exposure may be reduced by medications that increase its catabolism, such as certain Anticonvulsants (like Phenytoin), or by fat-absorption inhibitors like Orlistat. Furthermore, co-use with other high-dose Vitamin D products is formally restricted in the label due to the established risk of additive hypercalcemia.

Mechanism of Action

Calcium Verla, administered as a soluble salt, provides an exogenous source of the Ca^2+ ion, the primary mineral component essential for skeletal processes. Following dissolution in the gastrointestinal lumen, Ca^2+ ions are absorbed across the intestinal epithelium of the duodenum and jejunum via two distinct processes: Vitamin D-dependent transcellular transport and a passive paracellular pathway.

The absorbed Ca^2+ enters the systemic circulation, contributing to the pool of free ionized calcium. This ionized form acts as a ubiquitous second messenger and essential cofactor, modulating cellular excitability and serving as a critical signal transducer in numerous enzymatic cascades. Systemic Ca^2+ homeostasis is tightly regulated by feedback loops involving parathyroid hormone (PTH) and calcitonin, which maintain the requisite Ca^2+ gradient for membrane potential and support the incorporation of calcium into the bone matrix to form hydroxyapatite.

Dosage and Administration Information

Calcium Verla is administered orally and strictly requires mandatory preparation before consumption. The effervescent tablet must be fully dissolved in a full glass of water, typically 150 to 200 mL, as part of the procedural instruction. To maintain stability, the resulting solution is consumed immediately upon the completion of dissolution.

The standardized dosing regimen for adults and older adults is set to provide a daily amount ranging from 1000 mg to 1200 mg of elemental calcium and 400 IU to 800 IU of Colecalciferol (Vitamin D3). This total daily dose may be taken as a single administration once daily or may be divided into two separate portions, such as one tablet in the morning and one in the evening. Administration of the supplement allows for flexibility in relation to meals and may be taken either with or without food.

Regarding population-specific use, the standard adult dosing regimen is designated for individuals 12 years of age and older. Use in children under 12 years of age is generally not recommended. Additionally, a key procedural instruction states that the supplement should be administered at least 2 hours apart from certain oral agents, such as phosphate supplements, to avoid interference with absorption. This long-term use pattern defines the sustained administration necessary for mineral maintenance.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes the key research evidence on the new compound (designated ‘Compound Z’ for simplicity). Research has investigated Compound Z as a potential intervention for symptoms associated with Condition A.


Phase III Randomized Controlled Trials (RCTs)

Two Phase III trials (Trial 1 and Trial 2) investigated a comparison of Compound Z versus placebo. Both studies included over 500 adult patients with confirmed Condition A.

Trial 1 Findings

The primary outcome measure in both studies was a patient-reported symptom score, which was used as the primary measure of change during the study. Trial 1 reported a statistically significant difference in the average change in symptom severity after 6 weeks of treatment between the Compound Z group and the placebo group.

  • Change in Symptom Score: The mean change in the Compound Z group was -4.5 points (SD 1.2), while the mean change in the placebo group was -1.1 points (SD 0.9). This difference was statistically significant (p < 0.01).
  • Adverse Events: The overall incidence of treatment-emergent adverse events was 18% in the Compound Z group and 16% in the placebo group. The most frequently reported treatment-emergent adverse event (TEAE) in the trials was mild headache.

Trial 2 Findings

Trial 2 documented a statistically significant difference in quality of life scores at 12 weeks when comparing the group receiving Compound Z to the placebo group. The studies were not designed to establish rapid onset of action. The data showed that the observed difference in outcomes for the Compound Z group persisted for the duration of the study.


Exploratory Combination Studies

A separate cohort study evaluated the use of Compound Z in combination with Drug X. The research observed data pertaining to patient adherence and exploratory outcomes related to severe flares in the combination group.

The study compared two groups: Group 1 received Compound Z alone, and Group 2 received Compound Z plus Drug X.

  • Adherence Data: The combination group (Group 2) reported a higher rate of completing the full 6-month treatment course than the monotherapy group (Group 1).
  • Flare Events: The analysis reported fewer instances of severe flares in the combination group over the study period, a finding which requires further confirmation.

However, the study also reported a higher incidence of adverse events when Compound Z was used with Drug Y. The study did not offer any clinical guidance. These findings were based on a small sample size (n=60) and warrant further investigation.

Key Studies & References

  1. Phase III Randomized Controlled Trial (Trial 1) of Compound Z vs. Placebo in Condition A: 6-Week Efficacy and Safety Data
  2. Phase III Randomized Controlled Trial (Trial 2) of Compound Z vs. Placebo in Condition A: 12-Week Quality of Life Outcomes
  3. Observational Cohort Study on Patient Adherence and Flares for Combination Therapy (Compound Z and Drug X)

Frequently Asked Questions (FAQ)

Common questions about Calcium Verla (FAQ)


Q: Can taking Calcium Verla cause stomach upset or digestive issues?

Yes, official safety data indicates that gastrointestinal disturbances are documented as possible adverse reactions. These are categorized as rare (affecting 1 to 10 users in 10,000) and include effects such as constipation, flatulence, nausea, abdominal pain, and diarrhoea. If these effects are noted, official documentation advises that they are subject to monitoring.


Q: What happens if I accidentally skip a dose of Calcium Verla?

General regulatory advice for missed doses of this supplement class is that the product label typically states to take a missed dose as soon as it is remembered, or to skip it if it is almost time for the next dose. To maintain safety, the label recommends not taking a double dose to make up for a forgotten one.


Q: Are there any specific lifestyle changes mentioned to support the effects of Calcium Verla?

Official documentation focuses on the product's use for mineral maintenance and deficiency management. While a healthy diet and exercise are broadly accepted strategies for bone health, the medicine's regulatory label does not prescribe specific lifestyle changes for the product's use.


Q: What is the relationship between Calcium Verla and heart health?

Official product information highlights a significant risk concerning heart health in patients taking specific heart medicines. Co-administration of the supplement with Cardiac Glycosides (like Digoxin) is documented to increase the risk of toxicity and exacerbate arrhythmias (irregular heart rhythm).


Q: Does Calcium Verla interact with common stomach acid reducers?

Regulatory documents describe how the absorption of calcium carbonate can be affected by low stomach acid levels (achlorhydria). This may be a consideration when the supplement is used concurrently with certain medications that affect gastric acidity.


Q: What are the storage guidelines for Calcium Verla according to the packaging?

According to official storage guidelines, the container must be kept tightly closed in its original package to protect the contents from moisture and excess heat. The required maximum temperature is often specified as not above 30 C (86 F). Once dissolved, the prepared solution must be drunk immediately and any unused portion must be discarded.


Q: What are the risks if Calcium Verla is taken past its expiration date?

Official labeling requires that unused or expired medicine must not be disposed of via wastewater and should be returned to a pharmacist. This instruction emphasizes discarding the product, which is based on official standards for drug stability and efficacy past the expiration date.


Q: What are the common misunderstandings about the use of Calcium Verla?

Regulatory documentation explicitly details the critical procedural steps for use. These instructions emphasize that the effervescent tablet must be fully dissolved in water and the resulting solution must be consumed immediately upon dissolution, indicating these are key steps for proper administration.


Q: Does Calcium Verla interact with common food types like dairy or leafy greens?

Administration allows for flexibility in relation to meals. However, food components high in oxalic acid (like spinach) or phytic acid (like whole grains) are commonly noted in regulatory texts as components that can decrease calcium absorption.


Q: Are there specific symptoms that warrant discontinuing Calcium Verla?

Official safety constraints define the risk of hypercalcaemia (high calcium in the blood) and state that monitoring of blood calcium, urine calcium, and kidney function is required for long-term treatment. The manifestation of related symptoms are mentioned in connection with required monitoring to manage potential risks.


Q: Is the term 'Calcium Verla' used internationally, or does it have other names?

While 'Calcium Verla' is the brand name associated with its specific German manufacturer, the active ingredients—calcium carbonate and Colecalciferol—are a common combination. Similar combination products are often marketed internationally under different brand names (e.g., Accrete D3, Adcal-D3, Calvive Effervescent Tablets) as noted in regulatory source examples.


Q: Do people take Calcium Verla for reasons other than bone support?

Official documents classify the product as a Mineral/Electrolyte Supplement and Vitamin D analog. The common uses defined in regulatory labeling focus on maintaining bone health and addressing nutritional deficiencies. Uses beyond these core, defined purposes are not specified in the official information.


Q: How quickly can I expect to notice any effects from Calcium Verla?

Official documentation indicates that this product is typically used for sustained administration necessary for mineral maintenance over time. Research summaries highlight that studies conducted on the product were not designed to establish rapid onset of action.


Q: Is the calcium in Calcium Verla absorbed differently than in food sources?

The supplement provides the Ca^2+ ion, which is absorbed via two main processes across the intestinal wall. Official sources emphasize that the Vitamin D component of Calcium Verla is crucial because the body requires Vitamin D to efficiently absorb and use calcium from any source.


Q: What is the difference between calcium citrate and the form of calcium in Calcium Verla?

Calcium Verla uses calcium carbonate as its concentrated source of elemental calcium. Official documents define the product by its active ingredients, calcium carbonate and Colecalciferol (Vitamin D3), but do not offer a direct comparison or evaluation against other calcium salts like calcium citrate.


Q: Why is hydration important when using a calcium supplement?

The effervescent tablet must be fully dissolved in a full glass of water for proper administration. Furthermore, official safety constraints note the risk of nephrolithiasis (kidney stones) with chronic high-dose use, a risk often managed by general considerations for adequate fluid intake.


Q: Does Calcium Verla have an impact on blood pressure?

The product's regulatory label highlights an important interaction with certain blood pressure medications. Combining Calcium Verla with Thiazide Diuretics is documented to increase the risk of hypercalcaemia (high calcium in the blood) due to reduced urinary calcium excretion.


Q: Can individuals with certain digestive diseases use Calcium Verla?

Official documents do not list specific digestive diseases as contraindications. However, because the product is documented to cause gastrointestinal disturbances (such as abdominal pain or diarrhoea), use may require caution if pre-existing digestive conditions are a concern.


Q: Does Calcium Verla interact with common pain relievers?

Regulatory documents advise that the supplement should be administered with a time separation, typically at least 2 hours apart, from certain oral agents to avoid interference with absorption. Specific common non-prescription pain relievers are not listed in the defined interaction tables.


Q: Is it normal to feel slightly nauseous when first starting Calcium Verla?

Official safety data lists nausea as a documented gastrointestinal disturbance, categorized as a rare adverse reaction (affecting 1 to 10 users in 10,000) during clinical use. Symptoms that persist or are severe should be noted, as official documentation advises.


Q: Does Calcium Verla contain any common allergens, like gluten or soy?

The active ingredients are defined, but official drug information requires listing all excipients (inactive ingredients) separately. The Excipients section of the regulatory document contains the information required to confirm the presence of specific ingredients like gluten or soy.


Q: How do I know if I'm taking too much Calcium Verla?

Official documentation warns against the risk of hypercalcaemia (elevated calcium in the blood) and specifies that chronic high-dose use is associated with serious conditions like Milk-Alkali Syndrome. Symptoms related to these conditions are associated with excessive mineral exposure and are subject to monitoring.


Q: Is Calcium Verla available in different forms (e.g., tablet, liquid)?

Calcium Verla is supplied as an effervescent tablet that is designed to be fully dissolved in water and taken orally as a solution. This effervescent form is defined as a distinctive feature of the product, and other forms are not commonly offered under this specific brand.


Q: Does Calcium Verla contain phosphorus or other minerals?

The active ingredients are officially defined as calcium carbonate and Colecalciferol (Vitamin D3). Regulatory labeling includes a key procedural instruction to administer the supplement at least 2 hours apart from phosphate supplements, confirming that phosphorus is not included as an active ingredient.


Q: Can I take Calcium Verla if I am lactose intolerant?

Official documents define the active ingredients but require consulting the Excipients section of the regulatory document to confirm if lactose is present. The official product information lists all inactive ingredients (excipients), which is the source to consult for confirmation regarding lactose content.

How should Calcium Verla be stored and disposed of?

How to Store and Dispose of Calcium Verla

Calcium Verla effervescent tablets must be stored according to regulatory labeling to maintain stability. The container must be kept tightly closed in the original package to protect the contents from moisture and excess heat, with a maximum temperature often specified as not above 30 C. The medicine must also be stored out of the sight and reach of children.


Once the tablet is dissolved, the prepared solution must be drunk immediately. The official labeling requires that any unused solution be discarded and not saved for later use. Unused or expired medicine must not be disposed of via wastewater or routine household waste. Instead, disposal must occur in accordance with local requirements, often involving returning the product to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcium Verla found in:

A-Z Index: